COCH NASDAQ Week ended 07 Aug 2026

Weekly Investor Report

Envoy Medical Inc. · Healthcare · Medical Devices

Open interactive chart View report data
Latest close 0.67 USD
0.1% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -0.6% below the Trend Line and sits at 20.2% of its 52-week range. The latest completed week returned 0.1%, after a -1.8% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 0d.

Setup score 25 out of 100
Latest Close 0.67 USD 7 Aug 2026
1W Return 0.1% latest completed week
4W Return -1.8% short-term follow-through
12W Return 3.7% quarterly tape
Trend Breadth 5.8% 3 of 52 weeks active
Volume Ratio 0.3x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.1% Latest completed week; four-week move -1.8%. Indicator stack 3/65 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 52/100 14 relevant articles in the latest sentiment read. Event risk 0d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -0.6% below the Trend Line and sits at 20.2% of its 52-week range. The latest completed week returned 0.1%, after a -1.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0812-week average 0.07

12-week confirmation

Trend active3/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.08Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -1.8% over four weeks, 3.7% over 12 weeks, and -56.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W0.1%
4W-1.8%
12W3.7%
26W42.4%
52W-56.1%
Active trend streak0 weeks
Active weeks in one year3
Trend breadth5.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.68Latest activity-pressure read.
Pressure change34.1%Four-week change in activity pressure.
Leadership-25.30Latest relative-leadership reading.
RS change20.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 77%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength2/100Blend of value, momentum, and quality. Underlying universe rank 99; rank 1 is best.
Value17/100Relative valuation strength. Underlying universe rank 84; rank 1 is best.
Quality12/100Profitability and accounting quality. Underlying universe rank 89; rank 1 is best.
Momentum3/100Medium-term price momentum. Underlying universe rank 98; rank 1 is best.
Growth70/100Revenue and earnings growth. Underlying universe rank 31; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
220.9x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-74.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-310.7%
Gross profit retained from each unit of revenue.
Operating margin
-9407.7%
Operating profit retained from revenue.
Free-cash-flow margin
-8702.6%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
10.4%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
3.8%
Cash dividends relative to market value.
Buyback yield
-71.8%
Net share repurchases relative to market value.
Shareholder yield
-68.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 14 relevant articles.

6 positive · 8 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings0dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-64.5%Distance below the 52-week high.
13-week volatility6.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+27.3%Week of 13 Feb.
Worst week-18.1%Week of 10 Apr.
Latest week+0.1%Week of 7 Aug.

Shape of recent returns

Strong gains8
Modest gains7
Flat weeks0
Modest losses2
Sharp losses9
Recent vol6.0%13-week weekly-return volatility.
Base vol11.5%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew7.6% / -8.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape22/100

Trend, activity pressure, participation, and risk combine to a 22/100 tape read.

 Indicator analysis37/100

Latest 12-week confirmation: trend 3/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.08; No reversal markers Factors7/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 98; Small Cap Core rank 91 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment52/100

Weighted news tone is neutral across 14 relevant articles.

Envoy Medical (NASDAQ: COCH) raises cash, advances fully implanted cochlear implant Insiders50/100

No recent insider transaction evidence is stored.

 Earnings0d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20260.67 USD0.1%0.68 USD2.14 USD0.68-25.30509.5KOff
31 Jul 20260.67 USD1.2%0.68 USD2.20 USD0.66-23.62654.5KOn
24 Jul 20260.66 USD-5.5%0.68 USD2.26 USD0.85-25.941.5MOn
17 Jul 20260.70 USD2.7%0.68 USD2.33 USD0.90-24.833.9MOn
10 Jul 20260.68 USD-9.1%0.68 USD2.39 USD0.51-31.67977.9KOff
3 Jul 20260.75 USD12.8%0.68 USD2.45 USD0.42-25.381.8MOff
26 Jun 20260.67 USD5.1%0.69 USD2.51 USD0.20-34.8711.2MOff
19 Jun 20260.63 USD1.0%0.69 USD2.57 USD0.26-42.26552.4KOff
12 Jun 20260.63 USD-5.0%0.70 USD2.63 USD0.61-42.63542.4KOff
5 Jun 20260.66 USD-6.3%0.70 USD2.69 USD0.82-39.53848.7KOff
29 May 20260.71 USD-0.5%0.70 USD2.75 USD0.91-39.84361.9KOff
22 May 20260.71 USD9.6%0.70 USD2.81 USD0.96-39.25835.5KOff
15 May 20260.65 USD0.2%0.71 USD2.87 USD0.91-45.33545.7KOff
8 May 20260.65 USD-5.2%0.71 USD2.94 USD0.96-47.04557.6KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context